American Heart Journal
Volume 156, Issue 3 , Pages 549-555 , September 2008

Angiotensin inhibition in renovascular disease: A population-based cohort study

  • Daniel G. Hackam, MD, PhD

      Affiliations

    • Division of Clinical Pharmacology, University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationReprint requests: Daniel G. Hackam, Room 100K, Siebens Research Building 1400 Western Road, London, Ontario, Canada N6G 2V2.
    • ,
  • Minh L. Duong-Hua, MSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Muhammad Mamdani, PharmD, MA, MPH

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Ping Li, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Sheldon W. Tobe, MD

      Affiliations

    • Division of Nephrology, University of Toronto, Toronto, Ontario, Canada
    • ,
  • J. David Spence, MD

      Affiliations

    • Division of Clinical Pharmacology, University of Western Ontario, London, Ontario, Canada
    • ,
  • Amit X. Garg, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Division of Nephrology, University of Western Ontario, London, Ontario, Canada

Received 28 January 2008 ,Accepted 6 May 2008.

References 

  1. Hansen KJ, Edwards MS, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36:443–451
  2. Guo H, Kalra PA, et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation. 2007;115:50–58
  3. Knipp BS, Dimick JB, et al. Diffusion of new technology for the treatment of renovascular hypertension in the United States: surgical revascularization versus catheter-based therapy, 1988-2001. J Vasc Surg. 2004;40:717–723
  4. Fatica RA, Port FK, et al. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis. 2001;37:1184–1190
  5. Kalra PA, Guo H, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68:293–301
  6. Main J. Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death. Heart. 2005;91:548–552
  7. Spence JD. Treatment options for renovascular hypertension. Expert Opin Pharmacother. 2002;3:411–416
  8. Yang JG, Hu D, et al. Angiotensin-converting enzyme inhibitor usage in patients with incidental atherosclerotic renal artery stenosis. Hypertension Research-Clinical & Experimental. 2004;27:339–344
  9. Hackam DG, Spence JD, et al. The role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50:998–1003
  10. Kumar A, Asim M, et al. Taking precautions with ACE inhibitors. A theoretical risk exists in patients with unilateral renal artery stenosis. BMJ. 1998;316:1921
  11. Onuigbo MA, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. Med Sci Monit. 2005;11:CR462–CR469
  12. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol. 1996;12:127–137
  13. Gomma AH, Fox KM. The EUROPA Trial: design, baseline demography and status of the substudies. Cardiovascular Drugs and Therapy. 2001;15:169–179
  14. Pfeffer MA, Domanski M, et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol. 1998;82:25–30
  15. Des Jarlais DC, Lyles C, et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94:361–366
  16. von EE, Altman DG, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577
  17. Levy AR, O'Brien BJ, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67–71
  18. Austin PC, Daly PA, et al. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290–296
  19. Lindsay MP, Kapral MK, et al. Validation of administrative databases using a registry data source: implications for research on quality of stroke care. Stroke. 2005;36:477
  20. Technical methods—Appendix 1. In:  Naylor CD,  Slaughter PM editor. Cardiovascular health and services in Ontario: an ICES Atlas. Institute for Clinical Evaluative Sciences; 1999;
  21. Lee DS, Donovan L, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–188
  22. Juurlink D, Preyra C, Croxford R, et al. Canadian Institute for Health Information Discharge Abstract Database: a validation study. Toronto: Institute for Clinical Evaluative Sciences; 2006;
  23. Richards J, Brown A, Homan C. The data quality study of the Canadian discharge abstract database.. In: Achieving data quality in a statistical agency: a methodological perspective.. Proceedings of Statistics Canada Symposium Issue 2001. Statistics Canada, Ottawa, Ontario, Canada. 2001;
  24. Data quality of the discharge abstract database following the first-year implementation of ICD-10-CA/CCI: final report. Ottawa, Ontario, Canada: Canadian Institute for Health Information; 2004;
  25. Cox JL, Melady MP, et al. Towards improved coding of acute myocardial infarction in hospital discharge abstracts: a pilot project. Can J Cardiol. 1997;13:351–358
  26. Jong P, Gong Y, et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation. 2003;108:184–191
  27. Safian RD, Textor SC. Renal artery stenosis. N Engl J Med. 2001;344:431–442
  28. Edwards MS, Craven TE, et al. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch Intern Med. 2005;165:207–213
  29. Mui KW, Sleeswijk M, et al. Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J Am Soc Nephrol. 2006;17:2069–2074
  30. Edwards MS, Hansen KJ, et al. Associations between renovascular disease and prevalent cardiovascular disease in the elderly: a population-based study. Vasc Endovascular Surg. 2004;38:25–35
  31. Uzu T, Takeji M, et al. Prevalence and outcome of renal artery stenosis in atherosclerotic patients with renal dysfunction. Hypertens Res. 2002;25:537–542
  32. Pillay WR, Kan YM, et al. Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br J Surg. 2002;89:737–740
  33. Cheung CM, Wright JR, et al. Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol. 2002;13:149–157
  34. Conlon PJ, Little MA, et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001;60:1490–1497
  35. Bates MC, Campbell JE, et al. Factors affecting long-term survival following renal artery stenting. Catheter Cardiovasc Interv. 2007;69:1037–1043
  36. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241–249
  37. Alfonzo AV, Isles C, et al. Potassium disorders—clinical spectrum and emergency management. Resuscitation. 2006;70:10–25
  38. Devoy MA, Tomson CR, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med. 1992;232:493–498
  39. Johansen T, Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrology. 2001;2:1
  40. Kothari SS. ACE inhibitors and unilateral renal artery stenosis—what price?. Int J Cardiol. 1996;53:199–201
  41. Kindler J, Konrads A, et al. Progressive reversible kidney insufficiency after blood pressure reduction with captopril. Internist (Berl). 1981;22:360–363
  42. Collste P, Haglund K, et al. Reversible renal failure during treatment with captopril. Br Med J. 1979;2:612–613
  43. Cooper CJ, Murphy TP, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152:59–66
  44. Tullis MJ, Caps MT, et al. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis. 1999;33:675–681
  45. Franklin SS, Smith RD. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med. 1985;79:14–23
  46. Hodsman GP, Brown JJ, et al. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. J Hypertens Suppl. 1983;1:109–117
  47. Ogihara T, Kaneko Y, et al. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am J Hypertens. 1991;4:42S–45S
  48. Reams GP, Bauer JH. Enalapril versus triple-drug therapy in the treatment of renovascular hypertension. Drugs. 1985;30(Suppl 1):59–69
  49. Schwietzer G, Oelkers W. The antihypertensive effect of captopril in severe essential, renovascular, renal and transplant renovascular hypertension. Klin Wochenschr. 1982;60:839–846
  50. Papanikolaou PN, Christidi GD, et al. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174:635–641
  51. Casas JP, Chua W, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033
  52. Strippoli GF, Craig M, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828
  53. Jafar TH, Stark PC, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–252
  54. Siebenhofer A, Plank J, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med. 2004;21:18–25
  55. Rucinska EJ, Small R, et al. High-risk patients treated with enalapril maleate: safety considerations. Int J Cardiol. 1989;22:249–259
  56. van de Ven PJ, Beutler JJ, et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int. 1998;53:986–993
  57. Jackson B, Matthews PG, et al. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet. 1984;1:225–226

 The study was supported by an unrestricted research grant from the University of Western Ontario, London, Ontario, Canada. None of the funding sources participated in the design or conduct of the research; collection, management, analysis, or interpretation of the data; or the preparation, review, and approval of the manuscript.

 No conflicts of interest exist for D.G.H., M.L.D., M.M., P.L., or A.X.G. J.D.S. has consulted for Novartis and received lecture fees from Solvay. SWT has participated in research studies, advisory panels, and lectures with support from AstraZeneca, Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, Merck, and Novartis.

PII: S0002-8703(08)00385-2

doi: 10.1016/j.ahj.2008.05.013

American Heart Journal
Volume 156, Issue 3 , Pages 549-555 , September 2008

Article Tools

* Image Usage & Resolution